Neurovations Research announces open enrollment for the RELIEV-CM2 study to evaluate the ShiraTronics Migraine Therapy System.
Neurovations Research in Napa is proud to announce open enrollment for the RELIEV-CM2 study to evaluate the ShiraTronics Migraine Therapy System which is designed to provide relief, interruption, and prevention of migraine symptoms for chronic migraine sufferers.
ShiraTronics, a leader in neuromodulation technology, recently received approval from the U.S. Food and Drug Administration (FDA) to proceed with this pivotal Investigational Device Exemption (IDE) trial.
“We are excited to initiate the RELIEV-CM2 study and explore the potential of the ShiraTronics Migraine Therapy System,” said Dr. Grigsby. “This study represents an important milestone in our mission to bring innovative, effective treatments to those suffering from chronic migraine.”
In preparation for the study, Dr. Grigsby conducted an informative webinar for participants to outline the procedure and answer questions. The ShiraTronics Migraine Therapy System uses neuromodulation to deliver controlled electrical pulses along nerve pathways linked to chronic migraine symptoms.
Unlike traditional treatments that primarily address symptoms, the ShiraTronics system is designed to provide preventive, sustained relief for patients experiencing 15 or more headache days per month and who have not found success with other therapies.
For the millions living with the debilitating effects of chronic migraines, this novel approach could represent a significant breakthrough.
Key Details About the RELIEV-CM2 Study
- Objective: To assess the ability of the ShiraTronics Migraine Therapy System to reduce headache days and the intensity of chronic migraine attacks.
- Method: Neuromodulation therapy delivering mild electrical pulses along nerve pathways.
- Patient Control: Participants can manage their therapy through a dedicated application.
- Please visit ShiraTronics.com/clinical-trial to learn more about the RELIEV-CM2 clinical study.
Neurovations Research is currently enrolling participants for the RELIEV-CM2 study.
For more information and participation details, please visit: https://neurovationsresearch.com/migraine-study/ or call 707-252-9606.